Prostate cancer bone metastases: not so systemic after all
Mené sur 921 patients atteints d'un cancer de la prostate résistant à la castration et présentant des métastases osseuses, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité d'injections intraveineuses de radium-223
Radium-223 is a bone-homing,
α-emitting radiopharmaceutical approved for the treatment of men with castrate-resistant prostate cancer with bone metastases. In The Lancet Oncology , Oliver Sartor and colleagues 2 now extend their findings by reporting the effects of radium-223 on bone-specific symptoms. The ALSYMPCA trial is unique because it included patients with bone metastases only, and did not bias the results of the study with routine radiographic imaging that might have driven post-treatment ...
The Lancet Oncology , commentaire, 2013